drugset / Trial / NCT04275323
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of recombinant human hepatocyte growth factor (HGF) bare plasmid injection for local intramuscular injection in the treatment of patients with severe lower limb hemorrhagic disease (Rutherford grade 4)
Timeline
- Start
- 2019-08-02
- Primary completion
- 2024-06-03
- Completion
- 2024-06-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NL003 | Other / unclassified | 8 mg | Intramuscular |